-
3 days ago | 
bioworld.com | Shani Alexander
Home » Chipiron building ultra-low portable MRI scanner following $17M raise BioWorld briefs for May 12, 2025. BioWorld MedTech briefs for May 12, 2025. After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,... Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
-
4 days ago | 
bioworld.com | Shani Alexander
Chipiron building ultra-low portable MRI scanner following $17M Chipiron SA will produce a prototype of its ultra-low portable magnetic resonance imaging (MRI) scanner, after raising $17 million in series A financing, as it looks to make MRI more accessible. BioWorld MedTech Financings Series A Imaging Europe
-
1 week ago | 
bioworld.com | Shani Alexander
Investors unfazed by uncertainties around tariffs in med techDespite the uncertain macro environment created by the threat of reciprocal tariffs on goods into the U.S., some investors are still upbeat about the med tech sector. Even with changes at the HHS and disruption to product approvals throughout the FDA, venture capital investors remain cautiously optimistic. BioWorld MedTech Financings U.S.
-
1 week ago | 
bioworld.com | Shani Alexander
Precision Neuro leads BCI race following FDA clearanceThe recent 510(k) clearance by the U.S. FDA for a core part of Precision Neuroscience Corp. brain-computer interface technology is certainly a boon for the company, and others developing the devices. For the millions of people suffering from health disorders, such as motor neuron disease, spinal cord injury or severe stroke, its sign that a solution which could transform their lives could be just a few years away.
-
1 week ago | 
bioworld.com | Shani Alexander
Safeheal secures €35M for endoluminal fecal bypass systemSafeheal SAS raised €35 million (US$39.72 million) in an oversubscribed series C financing round for its temporary endoluminal fecal bypass system, Colovac, which is placed in the colon following colorectal resection. The funds will be used to complete an investigational device exemption pivotal study and speed up preparation for commercial launch of the device. BioWorld MedTech Financings Gastrointestinal Series C Europe
-
1 week ago | 
bioworld.com | Shani Alexander
Home » Aktiia SA raises $42M for BP monitoring platform, rebrands to Hilo BioWorld briefs for May 6, 2025. BioWorld MedTech briefs for May 6, 2025. The U.S. FDA has accepted the NDA for an oral formulation of Novo Nordisk A/S’s Wegovy (semaglutide) in treating obesity. If approved, the daily pill will be the... The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
-
2 weeks ago | 
bioworld.com | Shani Alexander
Home » Viromed signs deals for cold plasma technology devices BioWorld briefs for May 2, 2025. BioWorld MedTech briefs for May 1, 2025. The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the... The Trump administration’s broad slash to university research budgets raises pertinent questions over impacts to the biopharma ecosystem, specifically how a... BioWorld Asia briefs for April 22, 2025
-
2 weeks ago | 
bioworld.com | Shani Alexander
Home » Deepull raises €50M for bloodstream infection test BioWorld briefs for April 30, 2025. BioWorld MedTech briefs for April 30, 2025. The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the... KRAS mutations are found in more than 90% of pancreatic cancer cases, with the G12D variant being the most prevalent. BioWorld Asia briefs for April 22, 2025
-
2 weeks ago | 
bioworld.com | Shani Alexander
LSX World CongressEmerging markets presents opportunities for med tech Med tech companies were reminded that there are opportunities in emerging and growing markets as they look for ways to adapt to the uncertainties created by the U.S. administration threats of import tariffs. With large populations, and relatively untapped markets, these opportunities represent new destinations for the med tech products.
-
2 weeks ago | 
bioworld.com | Shani Alexander
LSX World CongressStartup, strategic relationship dependent on fair termsPartnership agreements between startups and strategics need to be based on terms that are fair otherwise they will be rejected. Inbrain Neuroelectronics SL turned down a term sheet agreement with Medtronic plc in favor of a deal with Merck & Co. as the terms were not fair, Carolina Aguilar, CEO and co-founder of Inbrain, told delegates at the LSX World Congress, in London. BioWorld MedTech Deals and M&A Europe U.S.
